Evidence map›Paper›PMID 41768041›Full record

ArticleEuropean urology open science2026

Richard Weiten, Constantin Rieger, Julian Heidenreich, Yuri Tolkach, Thomas Stehle, Florian Schmid, Teresa Schmidt, Martin Glas, Tobias Blau, Kathy Keyvani and 6 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Richard WeitenDepartment of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany.
Constantin RiegerDepartment of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany.
Julian HeidenreichDepartment of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany.
Yuri TolkachInstitute of Pathology, University Hospital Cologne, Cologne, Germany.
Thomas StehleInstitute of Neuropathology, University Hospital Cologne, Cologne, Germany.
Florian SchmidDepartment of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany.
Teresa SchmidtDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Martin GlasDepartment of Neurology and Neurooncology, St. Marien Hospital, Lünen, Germany.
Tobias BlauInstitute of Neuropathology, University Hospital Essen, Essen, Germany.
Kathy KeyvaniInstitute of Neuropathology, University Hospital Essen, Essen, Germany.
Thomas BüttnerDepartment of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.
Viktor GrünwaldClinic for Internal Medicine (Tumor Research) and Clinic for Urology, Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, University Hospital Essen, Essen, Germany.
Michael HölzelInstitute of Experimental Oncology, University Hospital Bonn, Bonn, Germany.
Axel HeidenreichDepartment of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany.
Markus EcksteinInstitute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Niklas KlümperDepartment of Urology and Paediatric Urology, University Hospital Bonn, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patient summary: We found that tumor samples from patients with cancer of the urinary tract that had spread to the brain had higher expression of a gene called NECTIN4 (67%). Our findings suggest that treatments targeting NECTIN4, such as a drug called enfortumab vedotin with or without pembrolizumab, might benefit patients with brain metastases, especially if their tumors have high NECTIN4 levels.

Indexed as

Antibody-drug conjugateCentral nervous systemMetastasesNECTIN4Urothelial carcinoma

Identifiers

PMID41768041
PMCPMC12936467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.